AI analytics can be used as imaging biomarkers for predicting invasive upgrade of ductal carcinoma in situ.

Jiyoung YoonJuyeon YangHye Sun LeeMin Jung KimVivian Youngjean ParkMiribi RhoJung Hyun Yoon

Published in: Insights into imaging (2024)

• Predicting ductal carcinoma in situ upgrade is important, yet there is a lack of conclusive non-invasive biomarkers. • AI-CAD scores-raw numbers, ≥ 50%, and ≥ 75%-predicted ductal carcinoma in situ upgrade independently. • Quantitative AI-CAD results may help predict ductal carcinoma in situ upgrade and guide patient management.

Keyphrases

artificial intelligence
coronary artery disease
high resolution
big data
case report